HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $15.00 target price on the stock.

Other equities analysts also recently issued reports about the company. Needham & Company LLC decreased their price target on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday. Wedbush reissued an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research note on Wednesday.

TScan Therapeutics Stock Down 5.0 %

TCRX opened at $1.92 on Thursday. TScan Therapeutics has a 1 year low of $1.82 and a 1 year high of $9.69. The firm has a 50 day moving average price of $2.45 and a 200 day moving average price of $4.06. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The company has a market cap of $102.47 million, a PE ratio of -1.81 and a beta of 0.87.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. Sell-side analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TCRX. State Street Corp increased its stake in TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after acquiring an additional 148,414 shares during the period. abrdn plc raised its stake in shares of TScan Therapeutics by 137.8% in the fourth quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after purchasing an additional 512,049 shares in the last quarter. Geode Capital Management LLC lifted its position in TScan Therapeutics by 8.1% in the third quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock worth $4,849,000 after purchasing an additional 72,967 shares during the period. Stifel Financial Corp boosted its stake in TScan Therapeutics by 3.9% during the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after buying an additional 3,733 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of TScan Therapeutics in the 3rd quarter valued at $112,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.